Novan is a pharmaceutical company focused on dermatology and anti-infective therapies. Co. has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. Co. has also introduced a possible anti-viral product candidate for the treatment of external genital warts (SB207). Co. has conducted or is conducting preclinical work on new chemical entities, including berdazimer sodium, and formulations for the potential treatment of SARS-CoV-2, the virus that causes COVID-19 (SB019); and antimicrobial indications for the adjacent companion animal health market (NVN4100). The NOVN stock yearly return is shown above.
The yearly return on the NOVN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NOVN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|